Does Estrogen Cause Melasma? Other Factors Needed

Estrogen Sensitizes Melanocytes but Cannot Act Alone

Estrogen primes melanocytes for overproduction, yet it requires at least one additional trigger to produce visible melasma. Human melanocytes express estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), and binding at these receptors increases tyrosinase activity, the rate-limiting enzyme in melanin biosynthesis [1]. A 2015 study published in the Journal of the American Academy of Dermatology confirmed that melanocytes from melasma-affected skin show increased ERα expression compared to adjacent normal skin [2].

But receptor activation alone does not explain the disease. Women with high circulating estradiol during the luteal phase of every menstrual cycle do not develop melasma automatically. The difference between estrogen exposure and clinical melasma is the presence of cofactors. UV radiation, genetic predisposition, and concurrent progesterone exposure each modify whether estrogen-driven melanocyte activation becomes visible hyperpigmentation [3]. Think of estrogen as a loaded trigger. Something else has to pull it.

This distinction matters for clinical decision-making. Women considering hormone replacement therapy or oral contraceptives often ask whether they will inevitably develop melasma. The answer depends on their total risk profile, not on estrogen exposure in isolation.

UV Radiation Is the Necessary Cofactor

Without ultraviolet exposure, melasma almost never appears. UV light is not merely an aggravating factor. It is the cofactor most consistently required alongside hormonal sensitization [4]. A study in Pigment Cell & Melanoma Research demonstrated that UV-B radiation directly increases stem cell factor (SCF) and endothelin-1 in keratinocytes, both of which stimulate melanocyte proliferation and melanin transfer to surrounding skin cells [5].

The mechanism is additive. Estrogen upregulates the melanogenic pathway from the melanocyte side. UV radiation amplifies it from the keratinocyte side. Together, these two inputs produce the sustained hyperpigmentation seen in melasma. A retrospective analysis of 324 melasma patients at a Brazilian dermatology referral center found that 97% reported sun exposure as either the initial trigger or the primary aggravating factor [6].

Visible light (400 to 700 nm wavelength) also plays a role, particularly in darker skin types. A randomized trial by Castanedo-Cazares et al. showed that visible light alone induced more prolonged and darker pigmentation in Fitzpatrick type IV subjects compared to UV-A exposure of equivalent energy [7]. This finding has shifted photoprotection recommendations. Iron oxide-containing sunscreens, which block visible light, now outperform traditional UV-only filters for melasma prevention [8].

Progesterone Adds a Second Hormonal Layer

Estrogen receives most of the attention, but progesterone is an independent contributor to melasma pathogenesis. The prevalence of melasma during pregnancy (15% to 50% depending on the population studied) peaks during the third trimester, when both estrogen and progesterone reach their highest concentrations [9]. If estrogen were the sole hormonal driver, melasma rates would track with estradiol levels across the menstrual cycle. They do not.

Progesterone receptors have been identified on human melanocytes, and in vitro exposure to progesterone increases melanin content in cultured melanocytes by 20% to 40% [10]. Progestin-only contraceptives (which contain no estrogen at all) have been documented to trigger melasma in susceptible individuals. A case series of 210 women using depot medroxyprogesterone acetate (DMPA) found melasma development in 9% of users within the first year [11].

The clinical implication is straightforward. Switching from a combined oral contraceptive to a progestin-only method will not necessarily protect against melasma. Both hormonal axes contribute, and counseling should address the combined risk rather than singling out estrogen.

Genetic and Skin Type Factors Determine Vulnerability

Melasma clusters in families and disproportionately affects people with darker constitutive pigmentation. A study of 324 women with melasma found that 48% had a first-degree relative with the condition [6]. Genome-wide association studies have not yet identified definitive melasma loci, but several candidate genes in melanogenesis pathways show preliminary associations [12].

Fitzpatrick skin type is the strongest demographic predictor. Melasma is most common in types III through V. It is uncommon in very fair skin (type I) and presents differently in type VI skin, where it can be harder to diagnose clinically. The biological explanation relates to baseline melanocyte density and activity: individuals with darker skin types have more active melanocytes that respond more vigorously to hormonal and UV stimulation [13].

Ethnicity tracks with these skin types. Populations of Latin American, South Asian, Middle Eastern, East Asian, and North African descent report the highest prevalence, ranging from 8.8% in a community-based study of Latino men and women in the United States to 40% in certain Southeast Asian populations [14]. This wide range reflects both genetic susceptibility and differences in UV exposure across geographic regions.

Genetic risk is not modifiable, but knowing it helps guide prevention. A woman with Fitzpatrick type IV skin, a family history of melasma, and plans to start combined oral contraceptives should receive proactive counseling about rigorous photoprotection before her first pill pack.

Oral Contraceptives and HRT: Quantifying the Risk

Combined oral contraceptives (COCs) are among the most commonly cited iatrogenic triggers of melasma. The estimated incidence ranges from 11% to 46%, with the wide range reflecting differences in study populations, skin types, UV exposure patterns, and formulation differences [15]. Higher-dose ethinyl estradiol formulations (50 mcg) carry greater risk than lower-dose pills (20 to 30 mcg), though direct comparative trials are limited [3].

For postmenopausal hormone therapy, the data are less extensive but still concerning. A prospective cohort study of 198 postmenopausal women starting estrogen-progestin therapy found melasma onset in 29% within the first year, with higher incidence in those with a prior history of pregnancy-related melasma [16]. Estrogen-only therapy appears to carry lower risk than combined estrogen-progestin therapy, which is consistent with the independent role of progesterone described above.

Transdermal estradiol may confer less melasma risk than oral formulations. Oral ethinyl estradiol undergoes first-pass hepatic metabolism, producing higher peak serum levels and more estrone conversion. Transdermal 17β-estradiol delivers steady-state levels without these peaks [17]. No randomized trial has directly compared melasma incidence between delivery routes, but several expert consensus panels recommend transdermal delivery for women with a history of melasma who require HRT [3].

The key clinical point: melasma risk from hormonal medications is dose-dependent, route-dependent, and modified by individual susceptibility. A woman with no family history, Fitzpatrick type II skin, and consistent sunscreen use may tolerate COCs without developing melasma. A woman with Fitzpatrick type IV skin and a mother who had chloasma gravidarum faces a substantially different risk calculation.

Prevention Strategies During Hormonal Exposure

Photoprotection is the single most effective intervention for preventing melasma onset and recurrence, regardless of hormonal status. A 2020 randomized controlled trial published in the Journal of the American Academy of Dermatology demonstrated that broad-spectrum SPF 50+ sunscreen with iron oxide reduced melasma severity (MASI score) by 52% compared to UV-only SPF 50+ sunscreen over 12 weeks, confirming the contribution of visible light [8].

Practical prevention during HRT or oral contraceptive use includes the following measures. Apply a broad-spectrum sunscreen with SPF 30 or higher (SPF 50 preferred) containing iron oxide every morning, regardless of cloud cover. Reapply every two hours during prolonged outdoor exposure. Wear wide-brimmed hats. Avoid tanning beds entirely.

For women with known risk factors starting hormonal therapy, some clinicians recommend prophylactic use of topical antioxidants (vitamin C 15% serum) or azelaic acid 15% to 20% to suppress early melanogenic signaling before visible pigmentation appears [18]. No randomized prevention trial has validated this strategy, so it remains an expert opinion-level recommendation.

If melasma develops during COC use, the decision to discontinue the contraceptive should weigh reproductive goals, availability of alternatives, and melasma severity. Mild melasma may be manageable with topical therapy and photoprotection alone, without requiring a change in contraceptive method.

Treatment Options When Melasma Develops

Triple combination cream (TCC) containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01% remains the most studied first-line topical treatment. A 2006 randomized controlled trial (N=641) found that TCC produced complete or near-complete clearing in 26.1% of patients at 8 weeks versus 4.5% to 7.8% for dual-agent controls [19]. The Cochrane Collaboration systematic review confirmed TCC's superiority over monotherapy with any single ingredient [20].

For patients who cannot tolerate hydroquinone or prefer non-hydroquinone options, alternatives include azelaic acid 20% (applied twice daily), tranexamic acid (oral 250 mg twice daily for 8 to 12 weeks), and cysteamine 5% cream. A 2020 meta-analysis of oral tranexamic acid for melasma pooled data from 11 studies (N=1,120) and found a mean MASI score reduction of 49% compared to 18% with placebo, with a low adverse event profile [21].

Chemical peels (glycolic acid 30% to 70%) and microneedling are adjunctive options. Neither replaces first-line topical or oral therapy, but both can improve treatment response when combined with standard protocols. Laser and light-based devices (Q-switched Nd:YAG 1064 nm, fractional 1550 nm) carry a risk of post-inflammatory hyperpigmentation, particularly in Fitzpatrick types IV through VI, and should be reserved for refractory cases under experienced supervision [22].

Maintenance therapy is mandatory. Melasma recurrence exceeds 50% within 12 months of treatment discontinuation if photoprotection lapses [3]. Long-term maintenance with a rotating regimen of azelaic acid, vitamin C, or low-concentration retinoids, combined with daily broad-spectrum sunscreen, is the standard of care.

The Multifactorial Model: Putting It Together

Melasma is best understood as a threshold disease. No single factor causes it. Instead, each contributing variable adds to a cumulative melanogenic load, and visible hyperpigmentation appears when that load crosses an individual's threshold.

Estrogen raises the load. Progesterone raises it further. UV radiation is the factor that almost always tips the balance. Genetic susceptibility determines how high or low the threshold sits. Visible light, heat exposure, and certain medications (phenytoin, phototoxic drugs) can add smaller increments.

This model explains several clinical observations that a single-cause theory cannot. It explains why not all pregnant women develop melasma despite uniformly high estrogen. It explains why melasma can develop in men (who have low estrogen but may have high UV exposure and genetic predisposition) [14]. It explains why melasma improves in winter and worsens in summer, regardless of hormonal status.

For clinicians managing women on HRT or contraceptives, the multifactorial model provides actionable guidance. You cannot eliminate hormonal exposure in a patient who needs it for menopausal symptoms or contraception. But you can aggressively reduce the UV and visible light contributions, which are often sufficient to keep total melanogenic load below the clinical threshold.

The most protective regimen for a high-risk patient starting HRT: daily SPF 50+ with iron oxide, a wide-brimmed hat for prolonged outdoor time, transdermal rather than oral estradiol delivery when clinically appropriate, and a low threshold for initiating prophylactic azelaic acid at the first sign of pigmentary change.